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Abstract
Purpose European Reference Network on Rare Endocrine Conditions' (Endo-ERN) mission is to reduce and ultimately
abolish inequalities in care for patients with rare endocrine conditions in Europe. This study assesses which themes related to
rare endocrine conditions are prioritized by patients for clinical research.
Methods A survey was developed, translated into 22 different European languages, and distributed to patients with rare
endocrine conditions. Patients were asked to give priority scores to listed prespecified topics: fertility, heritability, tiredness,
daily medicine intake, sleep quality, physical discomfort, and ability to work, partake in social life, and sports. They were
also asked to suggest further important areas for research in open fields.
Results After data cleaning, 1378 survey responses were analyzed. Most responses were received from Northern (47%) and
Western Europeans (39%), while Southern (11%) and Eastern Europe (2%) were underrepresented. Respondents were most
interested in research concerning ability to participate in social life and work. Patients suggested key areas to work: long-
term side effects of medical treatments and quality of life. Some priorities differed between disease groups, both for
prespecified and open topics and reflected aspects of patients’ individual conditions.
Conclusions With this large survey, Endo-ERN gained insight into patients’ unmet needs in scientific research. Patients
prioritized research on ability to work and participation in social activities, though needs differ between the disease groups.
Clinical experts should incorporate the results of this survey into the design of future studies on rare endocrine conditions.
We aim to utilize these results in designing patient-reported outcome measures for the disease areas covered by Endo-ERN.
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Introduction
In 2017, 24 European Reference Networks (ERNs) were
installed with the mission to reduce health care inequalities
for all patients with rare and/or complex conditions across
the European Union. This is to be achieved through cross-
border expert consultation and guideline conformity
enabling the highest standard of care [1]. The European
Reference Network on Rare Endocrine Conditions (Endo-
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ERN), at present, is the largest ERN, and comprises 86
reference centres representing 26 countries. These reference
centres are specialized in endocrine services, selected by
Endo-ERN based on strict criteria, and acknowledged as
centres of expertise by the EU. Endo-ERN has defined its
mission in five work packages (WPs): Education and
Training, Electronic-Health and Information and Commu-
nication Technology, Research and Science, Quality of
Care and Patient View and Diagnostics and Laboratory
analysis, and has identified eight organ- and physiology-
based main thematic groups (MTGs): Adrenal, Disorders of
calcium and phosphate homoeostasis, Genetic disorders of
glucose and insulin homoeostasis, Genetic endocrine
tumour syndromes, Growth and genetic obesity syndromes,
Pituitary, Sex development and maturation and Thyroid (see
the Endo-ERN website for a figure on the structure of Endo-
ERN) [2, 3].
The Research and Science WP aims to facilitate research
in the field of rare endocrine conditions and provide
recommendations to Endo-ERN members about relevant
research questions. Another important task of this WP is to
identify available research infrastructure and clinical trial
opportunities and facilitate their translation into feasible
research projects relevant to paediatric and adult endocrine
fields. These projects are then prioritized based on scientific
quality, relevance and available budget [4].
Involvement of patients is crucial to all ERNs. Endo-
ERN integrated patient representation already during the
construction phase of its network, with equal responsi-
bilities for patient representatives and health care provi-
ders. Each MTG and WP is co-chaired by two
endocrinologists, specialized in paediatric and adult
endocrinology, respectively, and at least one patient
representative. All patient representatives are endorsed
by their national organizations and have been approved
by Eurordis, the European umbrella organization for rare
disease patient organizations, and officially installed as
European Patient Advocacy Group representative. These
representatives ensure the presence of the patients’ voice
within the Network.
In recent times, patient involvement in the management
of their disease has become increasingly important. A
notable example is shared decision making, where physi-
cians provide all options and existing evidence to patients
and together both parties decide on the preferred approach
in the specific setting and circumstances. Disease outcomes,
however, have mostly been identified and studied by phy-
sicians so far. With the rise of value-based health care, more
studies have considered patient-reported outcome measures,
such as quality of life. However, the opinion of patients on
prioritized research topics is generally unknown and patient
involvement in decisions on research initiatives is minimal.
Therefore, when providing patients with all available
evidence, information on topics that are crucial to patients
may be lacking. This study aims to identify unmet needs in
medical research from a patient perspective, focusing on
rare endocrine diseases. In addition, it aims to identify
information resources preferred by patients in order to gain
access to most recent scientific information related to their
disease.
Methods
Construction of the survey
A survey containing 14 questions was constructed by the
Research and Science WP and Endo-ERN chairs. The sur-
vey was thereafter assessed on content and under-
standability by research specialists of Eurordis and PGO
Support (a public funded facilitator for patient organizations
in the Netherlands) whose comments and advice were used
to adjust the survey. The survey was translated on a
voluntary basis by patient advocates identified through the
Endo-ERN and Eurordis networks that were native speakers
of the target language into 22 different European languages:
Bulgarian, Croatian, Czech, Danish, Dutch, English, Esto-
nian, French, German, Greek, Hungarian, Islandic, Italian,
Lithuanian, Macedonian, Norwegian, Polish, Portuguese,
Slovakian, Slovenian, Spanish and Swedish. The survey
translators were invited to provide suggestions on the sur-
vey questions. The survey was distributed via heath care
providers affiliated to Endo-ERN, patient representatives,
national patient advocacy groups and via the Orphanet
newsletter. The survey was constructed with EUSurvey, a
survey tool provided by the European Commission, avail-
able at https://ec.europa.eu/eusurvey/home/welcome. Sur-
vey responses of rare endocrine disease patients (or their
parents and or caregivers) were gathered between late 23
December 2019 and 1 April 2020.
Before starting the survey, patients gave their consent for
scientific analysis and publication of their answers. Baseline
questions were related to participants’ disease area, gender,
age group and membership of any patient organization.
Thereafter, patients were asked to rate the importance of
nine prespecified topics in scientific research on a three-
point numerical priority rating scale with 1 corresponding to
“very important”, 2 to “important” and 3 to “less impor-
tant”. The prespecified topics were heritability, fertility,
tiredness, ability to participate in sports, ability to work,
ability to take part in social activities, daily medicine intake,
sleep quality and physical discomfort. In addition, patients
were asked what disease-related subjects “keep them up at
night” and were given the possibility to provide additional
suggestions for important research topics in open fields.
Finally, they were asked to indicate the most important
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sources of scientific information on their disease via
check boxes.
After distribution of the survey by the Swedish Thyroid
patient advocacy group, a disproportionately high number
of responses containing references to hypothyroidism were
received. This raised suspicion that not only patients with a
rare thyroid disease responded, but also patients who have
more common thyroid disorders. Therefore, responses by
Swedish thyroid patients not specifically mentioning rare
thyroid disorders were excluded from analysis.
Statistical analysis of quantitative data
Europe was divided into four regions in concordance with
the definition used by the United Nations Statistics Division
[5]. Statistical analysis of quantitative data was performed
using IBM SPSS statistics 25.0 (IBM Corp. Released 2017.
Armonk, NY, USA). Descriptive statistics were used to
describe and present the cohort. To assess differences in
rated importance between research topics, paired samples t-
tests were performed. To assess the difference of rated
importance of topics between groups (e.g., sex, MTG,
region), one-way ANOVA tests were performed with post
hoc t-tests with Bonferroni correction; significance was
taken at p < 0.05.
Analysis of open field data
Google Translate Application Programming Interface with
automatic source language detection was used to translate
all answers to English. During analysis, all responses to an
open field question were combined and weighted equally.
Thereafter, two survey questions concerning urgent research
areas were combined. To determine the most important
topics overall, we used a topic modelling technique called
non-Negative Matrix Factorization [6]. This algorithm
computes optimal clustering of words used in survey
responses, representing underlying topics. Words are
weighted with “Term Frequency—Inverse Document Fre-
quency” score: a statistical measure relevance. Number of
word appearances (i.e., its term frequency) is multiplied by
how common the word is in all responses (i.e., its inverse
document frequency). Thereby, words that are common to
every survey response (like “the” or “and” but also words
relating to survey questions) get a low weight and do not
affect the topic modelling. To ensure that frequently
occurring words do not impact topic modelling, highly
frequent words in English (also coined stop words) are
excluded. Non-Negative Matrix Factorization does not
determine the number of topics automatically, but clusters
words optimally given the number of topics “k”. “k” was
determined by choosing the number of topics for which
average coherence within topics was highest. Topic
coherence was measured using TC-W2V metric [7]. This
metric requires words to be mapped to numeric vectors
based on the context of the word [8]: words with similar
meanings end up with similar numerical representations and
how close these numerical vectors are (i.e., their cosine
similarity) can be used to measure how similar the words
are. The average cosine similarity of words belonging to a
topic is its TC-W2V coherence. Topic labels were assigned
manually by exploring words with the highest weights for
that topic.
Due to small size of the data, topic modelling could not be
used per MTG. Instead, we used the Kullback–Leibler diver-
gence for Informativeness and Phraseness metric [9] to iden-
tify the most distinctive phrases (maximum four words) per
MTG. Kullback–Leibler divergence is a measure from infor-
mation theory that estimates the amount of information that is
lost if probability distribution A is used to approximate
probability distribution B. To this end, the survey responses
(distribution B) are compared to a background corpus (dis-
tribution A): a large set of Wikipedia pages (circa 3.5 million
words) [10] provided by Verberne et al. [9]. The informa-
tiveness of a term is then those terms for which the expected
loss of information is highest, i.e., terms that are (much) more
frequent in responses than in the background collection. In
order to extract multi-word phrases instead of single words, the
phraseness of combinations of words is calculated. Phraseness
is a score for how likely terms are to occur together compared
to how likely they are to occur alone. The KLIP metric bal-
ances phraseness and informativeness with the parameter γ,
which was set at 0.8, as recommended by Tomokiyo et al. To
allow for grouping of different inflected forms of words, we
used lemmatisation, i.e., the linguistic process of reducing
words to their dictionary form or lemma (e.g., sleeping to sleep
or apples to apple). To improve the detection of phrases,
punctuation was excluded, and terms were not allowed to start
or end with stop words. Additionally, terms were not allowed
to span across different responses and had to occur at least two
times to be included. Finally, three- and four-word combina-
tions that occurred more than once in the answers of the same
person were removed in order to avoid biasing the results
towards one person’s opinion. Tables with outcomes of the
analysis are presented in the Supplementary files. The terms
were checked by an endocrinologist for relevance and direct




After data cleaning, 1378 survey responses were analyzed.
Demographic data are presented in Table 1 and Fig. 1. Most
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respondents were female (n= 1084, 79%); the majority of
respondents were members of a patient advocacy group
(69%). Southern (11%) and especially Eastern Europe (2%)
were poorly represented. Most responses were received from
patients of the Adrenal (39%), Pituitary (29%) and Thyroid
(13%) MTGs, whereas the Genetic disorders of glucose and
insulin homoeostasis MTG had the lowest representation
(2%). In spite of additional effort, no extra subjects could be
identified for underrepresented MTGs.
Priorities of suggested research topics
Patients rated ability to take part in social activities as the
most important suggested research topic (priority score: 1.26 ±
0.57), closely followed by ability to work (1.27 ± 0.57) and
physical discomfort (1.27 ± 0.58). A second tier of topics
consisted of tiredness (1.30 ± 0.61), sleep quality (1.33 ± 0.61)
and daily medicine intake (1.36 ± 0.66). Patients had the least
interest in research concerning heritability (1.55 ± 0.73), ferti-
lity (1.73 ± 0.76) and ability to participate in sports (1.75 ±
0.74) (Fig. 2).
Female respondents were significantly more interested in
research on fertility than male respondents (priority score:
1.70 ± 0.76 vs. 1.86 ± 0.75, p= 0.008). There were no further
gender-specific differences in the interest on the suggested
research topics (Supplementary Table S1). Respondents from
the Adrenal, Pituitary and Thyroid MTGs were more inter-
ested in research on tiredness than others (p < 0.001). Patients
from the Adrenal MTG were also more interested in research
on daily medicine intake than other respondents and rated this
as the most important suggested research topic (1.21 ± 0.54,
p < 0.001). Respondents of Sex Development and Maturation
MTG were more interested in research on fertility (1.30 ± 0.58,
second most important topic, p < 0.001) and less interested in
research on heritability (1.97 ± 0.85, least important topic, p <
0.001) than patients from other MTGs (Table 2). Respondents
from Southern Europe were more interested in the ability to
participate in sports than respondents from Northern Europe
(p= 0.002). Patients from Western Europe were more inter-
ested in research on physical discomfort than patients from
Northern Europe (p= 0.012). Comparisons between regions
were, however, not corrected for the difference in representa-
tion of MTGs.
What keeps patients up at night
When analyzing all responses, the most important subject
was pain, mainly in joints and muscles. Other frequently
mentioned subjects were chronic fatigue, quality of life,
daily medication and its dosage and long-term side effects
of drugs (Supplementary Table S2A).
In general, mentioned subjects were very disease specific.
Adrenal MTG patients mentioned adrenal crisis as the most
important subject that kept them awake. Genetic Endocrine
Tumour Syndromes MTG patients mentioned uncertainty
about the future and their family, while Sex Development and
Maturation MTG patients are particularly worried by hearing
loss. Pituitary patients frequently mentioned restless legs,
adrenal crisis and blood pressure as particular reasons for
concerns, whereas thyroid patients mentioned rest complaints
and energy levels (Supplementary Table S3A).
Urgent and so far insufficiently covered research
topics according to patients
Patients most often mentioned better treatment, in parti-
cular medication, as a research topic they want scientists

















Disorders of calcium and phosphate homoeostasis 46 (3.3)
Genetic disorders of glucose and insulin
homoeostasis
22 (1.6)
Genetic endocrine tumour syndromes 75 (5.4)
Growth and genetic obesity syndromes 48 (3.5)
Pituitary 398 (28.9)
Sex development and maturation 70 (5.1)
Thyroid 180 (13.1)
Region
Eastern Europe 26 (1.9)
Northern Europe 649 (47.1)
Southern Europe 146 (10.6)





Member of patient advocacy group 944 (68.5)
MTG main thematic group
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to focus on. Additionally, they request research on long-
term side effects of drugs. They also want researchers to
investigate quality of life, chronic fatigue and causes of
rare endocrine diseases (Supplementary Table S2B).
Adrenal patients rate increased research efforts on
emergency (glucocorticoid) injections and circadian
rhythm urgently necessary. Patients with Genetic dis-
orders of Glucose and Insulin Homoeostasis request
research on muscle weakness and dental effects of their
disease, while Genetic Endocrine Tumour Syndromes
patients list gene therapy and mental health as important
research topics. Mental health is also a theme suggested
by pituitary patients, as well as different endocrine con-
sequences of their disease, i.e., growth hormone (defi-
ciency), adrenal insufficiency and diabetes insipidus,
whereas patients from the Sex Development and
Maturation MTG want more research on hearing loss in
their disease. Thyroid patients would like more research
on radioactive iodine treatment (not further specified),
residual complaints (following treatment) and slow
release T3. No additional research topics were identified
by Growth and Genetic Obesity Syndrome patients
(Supplementary Table S3B).
Sources of information
Patients listed their treating endocrinologist as their main
source of scientific information (63.6%), followed by
websites (46.3%), patient advocacy groups (46.1%), social
media (41.0%) and other patients (30.4%) (Fig. 3). A sub-
stantial number (27.6%) of patients listed scientific litera-
ture as a source. Less often used sources of scientific
information were specialist reference centres (14.0%),
general practitioners (8.4%) and (specialized) nurses
(5.4%). The majority (54.8%) of respondents younger than
18 years listed their paediatrician/paediatric endocrinologist
as their main source of scientific information (Fig. 3).
Discussion
This study is the first large survey enabling rare endocrine
disease patients in the world to express their opinion on
unmet needs in medical research. It identifies which areas of
research they prioritize and what research they deem
urgently needed. From our list of nine prespecified topics of
research, functional outcomes “participation in social life”
Fig. 1 Absolute number of
responses per country
Endocrine (2021) 71:561–568 565
and “ability to work” are considered as most important
research topics by patients, irrespective of their particular
condition. While some recent clinical trials have made an
effort to include at least one measure on quality of life (e.g.,
SF-36 or AGHDA score in adult GH deficiency studies),
most studies in the endocrine field focus on clinician-
reported outcomes [11–15]. Identification of crucial func-
tional outcomes from patient’s perspective is therefore a
valuable observation. Additionally, patients urgently
request researchers to focus on long-term side effects of
medical treatment and patient-reported outcome measures,
such as quality of life and mental health. These results
concur with the results of pioneering studies performed in
the area of variations in sexual development where a
workshop was held on involvement of patients with atypical
sexual development and their parents [16] and a survey
among clinicians caring for these patients [17]. Clinicians
rated quality of life as the most urgent research topic within
this disease group [17], whereas patients and parents
pointed out that quality of life studies should also consider
gender development, sexual function and comorbidities.
Moreover, patients also suggested research on the long-term
effect of medication and on fertility preservation and
reproductive technology [16]. Research priorities differ
between disease groups and highlight particular character-
istics of different diseases. This study also assessed patients’






































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Mean priorities with standard deviations as rated by respondents
from 1 to 3 in order of prioritization, 1 being the most important
priority
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respondents (paediatric), endocrinologists are still the most
important and accessible source of information, but the fact
that over a third of patients do not list them as an infor-
mational source is of concern. In contrast, social media is an
emerging source of accessible information.
A clear bias towards the best represented groups was
observed, i.e., adrenal, pituitary and thyroid patients.
Therefore, future research efforts should particularly target
rare endocrine diseases that are underrepresented in this
study. Results were also analyzed for MTGs separately,
although power of quantitative comparisons and usefulness
of open field analyses is more limited, given the lower
number of respondents in each MTG. In open field analyses
of individual MTGs, suggested outcomes had to be inter-
preted by endocrinologists to select useful terms and topics,
which introduce interpretation bias.
During the distribution phase of this survey, we
observed large differences in the landscape of patient
representation in Europe. A well-established national
infrastructure of patient organizations is paramount in the
dissemination process of such a survey, as it allows to
contact their members directly. Eurordis provided valu-
able support and helped us to identify a high number of
patient organizations within Europe that are active on a
national or regional level. This greatly increased the
number of respondents. Some patient organizations were
far better represented than others (e.g., Danish adrenal,
German pituitary and Dutch thyroid cancer patient asso-
ciations) and this presumably reflects their level of
organization. For countries with no or few identified
patient organizations, it was more difficult or even
impossible to reach patients, resulting in clear under-
representation, which hampered data analysis.
In the designing phase of this survey, the importance of
addressing patients in their native language to increase
response rates became very apparent. Therefore, consider-
able effort was put in translation of the survey into 22
European languages. However, we noticed that the use and
literal translation of certain expressions resulted in inter-
pretation issues. For example, the question “what keeps
you up at night?” was intended to be interpreted figura-
tively and to identify major issues of concern for patients
with respect to their disease. However, many respondents
interpreted this expression literally, resulting in some
unintended answers. Moreover, when analyzing open field
data, all answers had to be translated back to English. We
used Google Translate Application Programming Interface
to do this automatically. However, this programme does
not perform as well for every language and especially
struggles with less common languages.
In conclusion, we report on a unique pan-European rare
endocrine patient survey on unmet needs in medical
research. An exceptionally high number of respondents
report on unmet needs, particularly in functional outcome
domains. These unmet needs differ between disease groups,
and, to a lesser extent, between gender and regions. Insur-
mountable hurdles were encountered to reach patients
residing in Eastern Europe, most probably related to lack of
effective patient organization infrastructure in this region.
We advise European policy makers and health care provi-
ders in these regions to invest additional research in iden-
tification of the reasons for this manifest inequality and to
prioritize measures that might reduce it. However, Endo-
ERN could provide aid in this matter and has this inequality
on its agenda. The results of this study should be embraced
by medical scientists in the design of future clinical studies
in the rare endocrine disease field.
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